Stock Analiz

Bristol Myers Squibb Co. (BMY) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Bristol Myers Squibb’s revenue went from $26.1B in fiscal 2019 to $48.2B in fiscal 2025, growth of about 10.7% a year.

Net income in fiscal 2025 was $7.1B, a net margin of 14.6%; the best year in this period was 2023 with $8.0B.

Over the twelve months to September 30, 2026, revenue was $50.0B and net income $9.2B.

Free cash flow was $12.8B in fiscal 2025 and positive in 7 of the 7 years shown.

The diluted share count rose 19% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $26.1B20192020: $42.5B20202021: $46.4B20212022: $46.2B20222023: $45.0B20232024: $48.3B20242025: $48.2B2025$48.2B
Net income
2019: $3.4B20192020: -$9.0B20202021: $7.0B20212022: $6.3B20222023: $8.0B20232024: -$8.9B20242025: $7.1B2025$7.1B
Free cash flow
2019: $7.4B20192020: $13.3B20202021: $15.2B20212022: $11.9B20222023: $12.7B20232024: $13.9B20242025: $12.8B2025$12.8B
EPS (diluted)
2019: $2.0120192020: $-3.9920202021: $3.1220212022: $2.9520222023: $3.8620232024: $-4.4120242025: $3.462025$3.46

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$50.0B$48.2B$48.3B$45.0B$46.2B$46.4B$42.5B$26.1B
Gross profit$34.6B$34.3B$34.3B$34.3B$36.0B$36.4B$30.7B$18.1B
Operating income$13.0B$9.3B-$8.4B$8.4B$7.7B$8.1B-$6.9B$5.0B
Net income$9.2B$7.1B-$8.9B$8.0B$6.3B$7.0B-$9.0B$3.4B
EPS (diluted)$4.51$3.46$-4.41$3.86$2.95$3.12$-3.99$2.01
R&D$10.6B$10.0B$11.2B$9.3B$9.5B$10.2B$10.0B$6.1B
Revenue growth—−0.2%+7.3%−2.5%−0.5%+9.1%+62.6%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow$10.7B$14.2B$15.2B$13.9B$13.1B$16.2B$14.1B$8.2B
Capital spending-$1.4B-$1.3B-$1.2B-$1.2B-$1.1B-$973M-$753M-$836M
Free cash flow$9.3B$12.8B$13.9B$12.7B$11.9B$15.2B$13.3B$7.4B
Dividends paid$5.1B$5.0B$4.9B$4.7B$4.6B$4.4B$4.1B$2.7B
Buybacks—$0$0$5.2B$8.0B$6.3B$1.5B$7.3B
Stock-based pay$552M$553M$507M$518M$457M$583M$779M$441M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$10.7B$10.9B$12.3B$9.3B$17.0B$15.8B$15.4B
Debt—$46.9B$51.0B$41.2B$40.4B$45.4B$51.3B$47.0B
Equity—$18.5B$16.3B$29.4B$31.1B$35.9B$37.8B$51.6B
Total assets—$90.0B$92.6B$95.2B$96.8B$109.3B$118.5B$129.9B
Shares (diluted)2.05B2.04B2.03B2.08B2.15B2.25B2.26B1.71B

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin69.2%71.1%71.1%76.2%78.0%78.6%72.3%69.1%
Operating margin26.0%19.4%-17.3%18.8%16.7%17.5%-16.2%19.0%
Net margin18.5%14.6%-18.5%17.8%13.7%15.1%-21.2%13.2%
FCF margin18.6%26.7%28.9%28.1%25.9%32.8%31.3%28.2%
ROIC—10.8%-9.8%11.4%8.9%8.6%-6.1%3.5%
ROE—38.2%-54.8%27.3%20.4%19.5%-23.8%6.7%

Frequently asked questions

What is Bristol Myers Squibb’s annual revenue?

$48.2B in fiscal 2025 and $50.0B over the twelve months to September 30, 2026.

How much profit does Bristol Myers Squibb make?

Net income was $7.1B in fiscal 2025 (net margin 14.6%).

Is Bristol Myers Squibb’s revenue growing?

No: revenue fell 0.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.